p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage

Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Therapy Combined With Chemotherapy and Radiotherapy in Treament of Head and Neck Cancer in Advanced Stage

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00894153

Enrollment

1200

Registered

2009-05-06

Start date

2009-05-31

Completion date

2013-06-30

Last updated

2012-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms

Keywords

p53 gene, head and neck malignent tumors, gene therapy

Brief summary

This is multicenter, open-label, randomized, active-controled, phase IV study of local direct intra-tumor injection of rAd-p53 monotherapy, with concurrent chemotherapy , with concurrent radiotherapy, or combination with surgery for treatment of head and neck malignant tumors in advanced stage .

Detailed description

Primary objectives of this study is to determine the efficacy profiles of rAd-p53 intra-tumor injection alone, with concurrent chemotherapy, with concurrent radiotherapy, or combination with surgery for treatment of head and neck malignant tumors in advanced stage (stage III or IV) including target lesion complete response rate (LCR) and overall target lesion response rate (OLR), response duration (RD), and progress-free survival (PFS). The secondary objectives of this study is to investigate overall response rate (OPCR) and overall complete response rate (OCR), overall survival (OS), ECOG, and safety of rAd-p53 monotherapy and combined with chemotherapy, radiotherapy or surgery.

Interventions

DRUGchemotherapy plus p53

chemotherapy plus p53

DRUGchemotherapy

chemotherapy

RADIATIONradiotherapy

radiotherapy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. Advanced stages of head and neck malignant tumors (stage III and VI) 2. At least one target tumor can be injected with study drug, the largest diameter greater than 2 cm 3. Histologically confirmed head and neck malignant tumors 4. No prior chemotherapy, radiotherapy or biological tumor therapy in 2 weeks 5. Age: 18-85 years old 6. Expected to survive more 12 weeks 7. ECOG:0-2 8. Neutrophils≥1.5×109/L,Platelet≥ 80×109/L, Hb≥80g/L, bilitubin≤2mg/dl,ALT and AST ≤2×institutional upper limit of normal, Cr ≤1.5×institutional upper limit of normal,coagulation tests (PTT and INR) within normal range 9. Subject provided signed informed consent

Exclusion criteria

1. Hypersensitive to study drug 2. Tumor(s) locate very close to important blood vessels and nerves, which affect injection 3. With a coagulation and bleeding disorder 4. With uncontrolled, intercurrent illness including but limited to symptomatic neurological illness, symptomatic congestive heart failure, unstable angina pectoris, significant pulmonary disease or hypoxia, or psychiatric illness 5. Local infection close to injection site or systemic infection 6. Pregnant or lactating 7. Principle investigator consider not suitable

Design outcomes

Primary

Measure	Time frame
Efficacy	3 years

Countries

China

Contacts

Primary ContactLongjiang Li, PhD

muzili63@163.com86-28-85503389

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026